Literature DB >> 10067946

Examining an affect regulation model of substance abuse in schizophrenia. The role of traits and coping.

J J Blanchard1, D Squires, T Henry, W P Horan, M Bogenschutz, J Lauriello, J Bustillo.   

Abstract

Comorbid substance use disorders occur frequently in schizophrenia with significant detrimental effects to clinical outcome. Unfortunately, attempts to identify factors associated with comorbid substance use disorders (beyond demographic characteristics such as gender) have not been successful. This study examined an affect regulation model of comorbid substance use in schizophrenia with a focus on personality traits and coping. It was hypothesized that maladaptive coping and the traits of negative affect (NA) and disinhibition (DIS), but not trait positive affect (PA), would be associated with greater substance use problems. Thirty-nine patients with schizophrenia or schizoaffective disorder completed measures of personality traits, coping, and negative consequences associated with substance use. Traits were differentially associated with coping in that NA and DIS, but not PA, were associated with maladaptive coping including the use of drugs and alcohol to cope with stress. Alternatively, PA, but not DIS or NA, was related to adaptive coping strategies. Individuals high in NA and endorsing the use of drugs and alcohol to cope reported the greatest number of negative consequences from substance use. This finding held after controlling for gender. These results are consistent with an affect regulation model of substance use and suggest the advantage of examining the role of affect, traits, and coping in understanding comorbid substance use in schizophrenia.

Entities:  

Mesh:

Year:  1999        PMID: 10067946     DOI: 10.1097/00005053-199902000-00002

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  11 in total

Review 1.  Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?

Authors:  Robert M Roth; Mary F Brunette; Alan I Green
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

Review 2.  Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Authors:  Alan I Green
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

Review 3.  Determinants of functioning and well-being among individuals with schizophrenia: an integrated model.

Authors:  P T Yanos; R H Moos
Journal:  Clin Psychol Rev       Date:  2006-02-09

Review 4.  Pharmacological treatment of schizophrenia and co-occurring substance use disorders.

Authors:  David A Smelson; Lisa Dixon; Thomas Craig; Stephen Remolina; Steven L Batki; Noosha Niv; Richard Owen
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  The Effectiveness of Supported Employment in People With Dual Disorders.

Authors:  Kim T Mueser; Kikuko Campbell; Robert E Drake
Journal:  J Dual Diagn       Date:  2011-05-11

6.  Do GluA1 knockout mice exhibit behavioral abnormalities relevant to the negative or cognitive symptoms of schizophrenia and schizoaffective disorder?

Authors:  Chris Barkus; Michael Feyder; Carolyn Graybeal; Tara Wright; Lisa Wiedholz; Alicia Izquierdo; Carly Kiselycznyk; Wolfram Schmitt; David J Sanderson; J Nicholas P Rawlins; Lisa M Saksida; Timothy J Bussey; Rolf Sprengel; David Bannerman; Andrew Holmes
Journal:  Neuropharmacology       Date:  2011-06-15       Impact factor: 5.250

7.  Personality domains, duration of untreated psychosis, functioning, and symptom severity in first-episode psychosis.

Authors:  Michael T Compton; Roger Bakeman; Yazeed Alolayan; Pierfrancesco Maria Balducci; Francesco Bernardini; Beth Broussard; Anthony Crisafio; Sarah Cristofaro; Patrick Amar; Stephanie Johnson; Claire Ramsay Wan
Journal:  Schizophr Res       Date:  2015-07-22       Impact factor: 4.939

Review 8.  Affective traits in schizophrenia and schizotypy.

Authors:  William P Horan; Jack J Blanchard; Lee Anna Clark; Michael F Green
Journal:  Schizophr Bull       Date:  2008-07-29       Impact factor: 9.306

9.  Social anhedonia and schizotypy in a community sample: the Maryland longitudinal study of schizotypy.

Authors:  Jack J Blanchard; Lindsay M Collins; Minu Aghevli; Winnie W Leung; Alex S Cohen
Journal:  Schizophr Bull       Date:  2009-10-22       Impact factor: 9.306

10.  Cognitive Enhancement Therapy Improves Frontolimbic Regulation of Emotion in Alcohol and/or Cannabis Misusing Schizophrenia: A Preliminary Study.

Authors:  Jessica A Wojtalik; Susan S Hogarty; Jack R Cornelius; Mary L Phillips; Matcheri S Keshavan; Christina E Newhill; Shaun M Eack
Journal:  Front Psychiatry       Date:  2016-01-12       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.